Christopher Ryan Sullivan Sells 10,185 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 10,185 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $17.62, for a total value of $179,459.70. Following the sale, the chief financial officer owned 39,900 shares of the company’s stock, valued at $703,038. The trade was a 20.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Stock Performance

AVTX traded down $1.03 on Friday, reaching $16.15. 2,525,345 shares of the company’s stock were exchanged, compared to its average volume of 1,145,632. The company’s 50 day moving average is $19.13 and its 200-day moving average is $17.06. The company has a market cap of $866.12 million, a price-to-earnings ratio of -3.70 and a beta of 0.78. Avalo Therapeutics, Inc. has a twelve month low of $9.54 and a twelve month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Sell-side analysts forecast that Avalo Therapeutics, Inc. will post -2.69 EPS for the current year.

Analysts Set New Price Targets

AVTX has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Bank of America began coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Wall Street Zen raised Avalo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Finally, Guggenheim set a $48.00 target price on Avalo Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG boosted its holdings in Avalo Therapeutics by 956.9% in the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after purchasing an additional 432,608 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Avalo Therapeutics by 556.4% during the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after purchasing an additional 101,814 shares during the last quarter. DV Trading LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $5,376,000. Seven Fleet Capital Management LP raised its position in shares of Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after purchasing an additional 510,540 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Avalo Therapeutics during the 1st quarter valued at approximately $849,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.